1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
EvoNext Holdings S.A.

EvoNext Holdings S.A.

ELVAF
EvoNext Holdings S.A.US flagOther OTC
2.15
USD
- -
- -
15.50MMarket Cap
EvoNext Holdings S.A.
ELVAF
(Other OTC)

Recent

price

2.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
26.37
13.98
7.99
7.55
6.66
5.58
4.6
3.55
2.9
3.76
2.4
2.81
3.63
1.75
- -
- -
Revenue per Share
-32.99
-28.34
-18.23
-13.65
-15.33
-18.93
-18.92
-20.21
-9.48
-7.02
-9.49
-11.72
-10.13
-19.5
0.14
-0.09
Basic EPS, GAAP
-25.45
-23.18
-15.98
-11.72
-15.18
-19.94
-18.41
-18.75
-11.84
-6.34
-9.2
-9.54
-4.94
-1.8
-0.34
-0.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.49
-13.21
-30.05
-24.49
-23.42
-29.94
-45.37
-26.74
-26.2
-31.52
-77.94
-78.45
-73.57
-77.23
-64.89
-64.98
Book Value per Share
50.89
3.93
-7.04
17.3
27.91
42.42
22.51
49.91
17.95
12.53
6.74
5.25
3.17
1.03
0.91
0.82
Tangible Book Value per Share
1
1
1
1
1
2
2
2
3
3
3
4
4
5
7
7
Basic Weighted Avg Shares
19
11
7
9
9
9
9
7
9
12
8
10
16
9
- -
- -
Sales/Revenue/Turnover
-124.07
-234.07
-284.96
-203.16
-265.21
-422.26
-480.09
-655.79
-344.09
-173.57
-330.27
-425.5
-259.93
-533.65
- -
- -
Operating Margin (%)
2
3
3
3
4
7
7
5
5
8
8
9
8
5
- -
- -
Depreciation Expense
-23
-22
-16
-16
-21
-32
-36
-39
-29
-22
-30
-41
-43
-105
1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-125.07
-202.63
-228.17
-180.7
-230.03
-339.29
-411.2
-569.28
-327.05
-186.61
-396.12
-417.78
-279.07
-1,114.98
- -
- -
Profit Margin (%)
33
17
1
22
49
81
51
95
52
36
18
18
11
7
7
6
Working Capital
4
6
4
3
4
4
4
2
2
5
4
4
3
- -
- -
- -
LT Debt
53
72
60
83
175
203
173
221
194
173
145
132
106
6
7
6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12.81
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.24
- -
Return on Capital (%)
-142.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-14.09%
-22.89%
-9.9%
Free Cash Flow
-19.29%
-40.64%
-53.14%
Net Income, GAAP
-6.94%
-15.53%
-162.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-19.5
2024
- -
- -
- -
- -
0.14
2025
- -
- -
- -
- -
-0.09

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Servoteach Industries Limited (SERVOTEACH.BO)
Biodexa Pharmaceuticals Plc (BDRX)
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Akari Therapeutics, Plc (AKTX)
Nautilus Biotechnolgy, Inc. (NAUT)
AnaptysBio, Inc. Common Stock When Issued (ANABV)
Business
Evolva Holding S.A. (Ticker: ELVAF) develops and commercializes sustainable ingredients using proprietary biotechnology processes for the flavor, fragrance, cosmetics, and life sciences industries. The company offers a portfolio of nature-identical ingredients, including Valencene for nootkatone production, nootkatone as a natural insect repellent and flavor compound, sclareol for fragrance applications, and specialty biotech-derived products such as resveratrol, vanillin alternatives, and saffron components; these are produced via fermentation technology that enables scalable, environmentally friendly manufacturing without reliance on traditional plant extraction or chemical synthesis. Evolva serves customers in food and beverage, personal care, consumer health, and pharmaceutical sectors, with operations spanning Europe, North America, and Asia. Founded in 2004 and headquartered in Reinach, Switzerland, the company focuses on high-value, biotech-enabled molecules targeting premium markets demanding natural and sustainable solutions. In recent developments, Evolva has pursued strategic expansions in its nootkatone platform through partnerships for commercial scaling and continued advancements in its fermentation technology suite to broaden ingredient offerings amid growing demand for biotech flavors and repellents.

Company News

APIChatGPT

  • seekingalpha.com

    Evolva Holding SA (ELVAF) Q2 2023 Earnings Call Transcript

  • seekingalpha.com

    Evolva Holding SA (ELVAF) Q4 2022 Earnings Call Transcript